Clinical Trials Browser

Phase 3 × Interventional × enfortumab vedotin × Clear all

Urinary Bladder Neoplasms

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT07566156 2026-05-11

EV-309

Phase 3 Recruiting

390 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT07346053 2026-01-16

Chrono-EVP

Phase 3 Not yet recruiting

224 enrolled

Genitourinary

Advanced Bladder Cancer

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 1 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Phase 3 Active not recruiting

595 enrolled 1 FDA

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

VOLGA

EV-302

EV-309

KEYNOTE-B15

Chrono-EVP

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

KEYNOTE-905